E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neurotransmitter in the brain. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Cognitive performance [Alzheimer's Disease Assessment Scale - Cognitive Items (ADAS-COG)]; Activities of daily living [Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)]. |
|
E.2.2 | Secondary objectives of the trial |
ADAS-COG+ [Modified Alzheimer's Disease Assessment Scale - Cognitive Items (ADAS-COG+)]; Global clinical impression of therapeutic effect [Clinician's Interview Based Impression of Change (CIBIC+)]; Behavioural / psychiatric symptoms [Neuropsychiatric Inventory (NPI)]. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
•Males of at least 50 years of age; •Females of at least 50 years of age, who are either at least 2 years post-menopausal or surgically sterile; •Probable Alzheimer’s disease consistent with National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria; •Have had a computed tomography (CT) or magnetic resonance imaging (MRI) brain scan within the 12 months prior to inclusion in the study that is indicative of probable Alzheimer’s disease; •A Mini-Mental State Examination (MMSE) score of between 12 and 24 (inclusive) at Visit 1 (screening); •A modified Hachinsky Ischemic Scale (mHIS) score equal to or below 4 at Visit 1 (screening); •Reliable caregiver available, and if not living in the same household, caregiver sees patient at least 4 times a week or a total of 15 to 20 hours per week; •Patients who do not need continuous nursing care and who are either living at home or in an institutional setting; •General health status acceptable for participation in a 6 month clinical study; •Is capable of understanding and has given written informed consent [or this has been provided by their acceptable representative (according to local requirements)] and a separate caregiver responsibilities and consent form has also been signed by the patient’s caregiver; •Agrees to comply with protocol requirements.
|
|
E.4 | Principal exclusion criteria |
General •Failure to perform or comply with screening or baseline examinations; •Hospitalisation (except for study purposes or due to social reasons, e.g. hospitalisation to unburden the caregiver); •Change of concomitant medication 4 weeks prior to screening or during screening period; •Participation in another therapeutic clinical study within the 3 months before Visit 2 (baseline); •Inability to swallow tablets.
Medical •Vitamin B12 or folate deficiency unless treated in which case treatment needs to have been stable for 3 months before study entry; •Hypothyroidism, defined as any thyroid-stimulating hormone elevation. Corrected hypothyroidism is allowed provided treatment has been stable for 3 months before study entry; •Juvenile onset diabetes mellitus; •Adult onset diabetes mellitus insufficiently controlled [Haemoglobin A1c (HbA1c) > 8%]; •A malignancy within the last 5 years; •HIV infection; •Any history of hepatic insufficiency or abnormal liver enzymes; •Renal insufficiency with abnormal serum creatinine outside the age appropriate normal range; •Serum electrolytes (sodium, potassium, magnesium) outside the age appropriate normal range; •Clinically significant abnormal laboratory values outside the age appropriate normal range; •Hypersensitivity to cholinergic drugs; •Uncontrolled asthma.
Cardiovascular •Myocardial infarction or unstable angina within the 6 months prior to Visit 1 (screening); •History of more than one myocardial infarction during the last 5 years; •Cardiomyopathy; •Myocarditis; •Severe hypotension; •Severe hypertension requiring treatment with more than 2 drugs; •Bradycardia (frequency of heart beat < 50/minute); •Tachycardia (frequency of heart beat > 90/minute); •Presence of AV block (type II / Mobitz II and type III); •Congenital long QT syndrome; •Sinus node dysfunction; •Prolonged QTcB-interval (males > 450 msec; females > 470 msec); •Presence of U wave.
Psychiatric •Axis I diagnosis within 1 year prior to study entry; •Previous diagnosis of bipolar affective disorder or schizophrenia; •Current alcohol or substance abuse or dependence; •Metabolic or toxic encephalopathy or dementia due to a general medical condition; •Geriatric Depression Score (GDS) > 5 at Visit 1 (screening).
Neurological •Stroke within the 6 months prior to Visit 1 (screening) or concomitant with onset of dementia; •Tumours, subdural haematoma or other space-occupying processes on CT/MRI; •Head trauma with loss of consciousness within 1 year of the onset of dementia; •Head trauma with loss of consciousness concurrent with the onset of dementia; •Onset of dementia within 1 year following cardiac arrest, surgery with general anaesthetic or resuscitation; •Degenerative central nervous system conditions e.g. Huntington’s disease (Huntington’s chorea), Creutzfeld-Jakob disease, Parkinson’s disease, etc.; •Genetic cognitive impairment e.g. Trisomy 21 (Down’s syndrome); •Wernicke’s encephalopathy; •Acute or chronic central nervous system infection including tertiary syphilis; •Epilepsy.
Previous Medication Has previously received: •Any acetylcholinesterase inhibitor in the 3 months before study entry; •Any experimental drug 3 months before Visit 2 (baseline); •Nootropics 1 month before Visit 1 (screening); •Benzodiazepines administered on a chronic basis; •Antipsychotics (unless prescribed for sleep disturbances) in the 3 months preceding study entry. If prescribed for sleep disturbance, then these should be discontinued 2 weeks prior to screening; •Antidepressants, except stable treatment with selective serotonin reuptake inhibitors (SSRIs) for at least 3 months prior to screening.
Concomitant Medication Needs concomitant use of, or treatment with the following: •Peripherally acting drugs with effects on cholinergic transmission; •Immunosuppressants; •Antiparkinsonian therapy; •Antiepileptics; •Centrally active anti-hypertensive drugs like clonidine, alpha methyl-dopa, guanidine, guanfacine or moxonidine; •Chronic intake of opioid containing analgesics or use within 3 days of a study visit; •Chronic intake of sedating antihistamines or acute use within 3 days of a study visit; •Chronic intake of systemic corticosteroids; •Any other medication not covered by the above that impacts upon cognition within 3 days of a study visit.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The following efficacy assessments will be conducted in this study: •ADAS-COG / ADAS-COG+; •ADCS-ADL; •Clinician’s Interview Based Impression (CIBI+) comprising the Clinician’s Interview Based Impression of Disease Severity (CIBIS+) or the Clinician’s Interview based Impression of Change (CIBIC+); •NPI.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 15 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 15 |